There is still no drug in the fight against corona. But now the WHO has included two anti-inflammatory drugs for the treatment of Covid-19 that give rise to hope.
Dortmund – There is still no specific drug against that Coronavirus*. However, companies are researching how Biontech and Pfizer are working flat out on a corona pill*. The pharmaceutical company hopes for approval in 2021. Until then, however, the symptoms of Covid 19 disease must continue to be treated. And in this regard, two new drugs give hope, like RUHR24* reported.
|United Nations specialized agency||World Health Organization (WHO)|
|founding||April 7, 1948|
|tasks||Realizing the best possible level of health and fighting disease worldwide|
Corona: So far no specific drug against Covid-19 has been discovered
Many different drugs that were originally developed to treat other diseases are currently used in the therapy of Covid-19. For example, Ebola, HIV or malaria drugs are used to counter the symptoms of corona disease.
Medicinal blood thinning, oxygen, antibiotics, cortisone and other anti-inflammatory drugs are also repeatedly used as treatment options. Which of these methods is used to treat Covid-19 depends on the respective patient and the course of the disease.
Corona: WHO takes on new drugs to treat Covid-19
The World Health Organization (WHO) is continuously expanding the list of drugs that are based on the latest medical findings Treatment of corona* are recommended. Since Tuesday (July 6th) this list is two more drugs longer. And they give hope when it comes to the death rate from corona disease.
Specifically, it is about tocilizumab and sarilumab – two active ingredients that were originally developed to treat rheumatic joint inflammation. The WHO recommendation was based on a study published in the American medical journal Jama.
Corona: Study gives hope for two drugs
The results are clear: In corona patients with severe disease, the administration of one of the two drugs reduced the risk of death by 13 percent. It is important, however, that those affected are always given the rheumatism drugs in conjunction with cortisone. However, so-called glucocorticoids are now standard in the treatment of severe Covid-19 courses.
The risk of a corona patient having to be ventilated is reduced by 28 percent compared to standard treatment. Specifically, this means: With 1,000 people infected with corona, there are 15 fewer deaths and 23 fewer people who have to be mechanically supplied with oxygen.
Medicines against corona: Rheumatism drugs could significantly reduce the risk of death
According to the WHO, patients with a severe corona course often suffer from an overreaction of the immune system, which can be extremely dangerous or even fatal for the health of the patient. The administration of the rheumatism active ingredients tocilizumab and sarilumab helps to suppress this overreaction and thus significantly lower the risk of death.
For the results, the so-called REACT working group (“Rapid Evidence Appraisal for COVID Therapies”) of the WHO had compiled and evaluated the experiences from 27 clinical studies with around 11,000 Covid-19 patients. WHO Director General Dr. Tedros Adhanom Ghebreyesus said of the study, “These drugs offer hope for patients and families suffering from the devastating effects of severe and critical Covid-19.”
New corona study gives hope: WHO criticizes the cost of the drugs
But in the same breath he also put a damper on the euphoria. The drugs are not yet available to a large part of the world’s population and are also too expensive. “The unfair distribution of vaccines means that people in low- and middle-income countries are most susceptible to severe forms of Covid-19.”
He continues: “Therefore, the greatest need for these drugs is in countries that currently have the least access. We urgently need to change that, ”the WHO chief continued. He therefore called on the pharmaceutical industry to significantly reduce the prices for the drugs and to make them available to the countries concerned.
Corona: Medicines too expensive for many – important appeal to the pharmaceutical industry
The organization Doctors Without Borders responded to this appeal and specifically addressed the Swiss pharmaceutical company Roche. Roche is the exclusive manufacturer of the drug tocilizumab and, according to Doctors Without Borders, prices range from $ 410 in Australia to $ 646 in India per 600 mg dose. Even though the manufacturing cost is estimated at only $ 40 per dose.
The organization therefore calls on the pharmaceutical manufacturer, especially during the Covid 19 pandemic, not to do any profitable business with drugs that could save lives. In addition, the know-how should be made available to other companies in order to guarantee global supply. * RUHR24 is part of the editorial network of IPPEN.MEDIA.
List of rubric lists: © OLGA MALTSEVA